MBP MAPK Substrate atriptan Treatment with 18β-Glycyrrhetinic acid at

Treatment with 18β-Glycyrrhetinic acid at 160 μM and 320 μM decreases the levels of full-length PARP and increases the levels of cleaved-PARP

Pomalidomide4PEG1acid

FK866 also reduces ATP levels in ML-2 cells due to the inhibition of NAD synthesis

InChi: InChI=1S/C28H26NO3P

Chemical Name: λ²-iron(2+) 15

MBP MAPK Substrate atriptan Treatment with 18β-Glycyrrhetinic acid atMBP MAPK Substrate is used as an exogenous substrate for MAPK. Product information CAS Number: 138028 00 9 Molecular Weight: 1081. 11 Formula: C41H71F3N18O13 Chemical Name: (2S) 2 [(2S) 2 [2 (2 {[(2S) 1 [(2S,3R) 2 [(2S) 2 {[(2S) 1 [(2S) 2 aminopropanoyl]pyrrolidin 2 yl]formamido} 5 [(diaminomethylidene)amino]pentanamido] 3 hydroxybutanoyl]pyrrolidin 2 yl]formamido}acetamido)acetamido] 5 [(diaminomethylidene)amino]pentanamido] 5